Compare VRTX & MAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | MAR |
|---|---|---|
| Founded | 1989 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Hotels/Resorts |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 94.9B |
| IPO Year | 2006 | 2005 |
| Metric | VRTX | MAR |
|---|---|---|
| Price | $426.38 | $361.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 16 |
| Target Price | ★ $539.69 | $359.31 |
| AVG Volume (30 Days) | 981.5K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.76% |
| EPS Growth | ★ 836.54 | 14.17 |
| EPS | 4.02 | ★ 9.51 |
| Revenue | $2,488,652,000.00 | ★ $26,186,000,000.00 |
| Revenue This Year | $10.79 | $304.38 |
| Revenue Next Year | $10.47 | $5.38 |
| P/E Ratio | ★ $27.74 | $37.29 |
| Revenue Growth | ★ 46.20 | 4.33 |
| 52 Week Low | $362.50 | $253.56 |
| 52 Week High | $509.98 | $380.00 |
| Indicator | VRTX | MAR |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 55.77 |
| Support Level | $403.16 | $312.30 |
| Resistance Level | $428.73 | $370.00 |
| Average True Range (ATR) | 8.32 | 8.66 |
| MACD | 0.22 | -2.20 |
| Stochastic Oscillator | 46.12 | 49.45 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Marriott operates 1.8 million rooms across roughly 30 brands. At the end of 2025, luxury represented roughly 10% of total rooms, premium was 42%, select service was 46%, and midscale was 2%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 99% of total rooms as of Dec. 31, 2025. North America makes up 61% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.